(RTTNews) - Journey Medical (DERM) announced the FDA has approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's ...

The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in adults, drugmaker Journey Medical announced on Monday. Approval of the ...

The FDA has approved an antibiotic called minocycline for the treatment of rosacea in adults. The drug, which is taken orally, will be sold under the brand name Emrosi.

FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea The long-term skin condition affects more than 16 million people in the US The US Food and Drug Administration (FDA) has ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder. The new capsule formulation of the ...

Journey Medical (NASDAQ:DERM) has received FDA approval for its drug Emrosi for the treatment of rosacea. Emrosi is the brand name for minocycline hydrochloride extended release 40 mg capsules ...

The approval of Emrosi is supported by positive data from Journey Medical’s two Phase 3 clinical trials for the treatment of rosacea. The Phase 3 clinical trials met all co-primary and secondary ...

The FDA approves Journey Medical's Emrosi, formerly known as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Journey Medical announces it's in the process of completing the ...

The approval Journey Medical received from FDA for Emrosi makes DERM an exciting stock. Click here to read more.

Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea ...

Emrosi™, also known as DFD-29, is a 40 mg Minocycline Hydrochloride Modified-Release Capsule, combining 10 mg immediate release and 30 mg extended release, administered once daily for 16 weeks.